Molecular docking analysis of 2009-H1N1 and 2004-H5N1 influenza virus HLA-B*4405-restricted HA epitope candidates: implications for TCR cross-recognition and vaccine development

doi:10.1186/1471-2105-14-S2-S21

BMC Bioinformatics. 2013; 14(Suppl 2): S21.

Published online 2013 January 21. doi: 10.1186/1471-2105-14-S2-S21

PMCID: PMC3549837

Molecular docking analysis of 2009-H1N1 and 2004-H5N1 influenza virus HLA-B*4405-restricted HA epitope candidates: implications for TCR cross-recognition and vaccine development

Chinh TT Su,¹ Christian Schönbach,^3,⁴ and Chee-Keong Kwoh^1,²

¹Bioinformatics Research Centre, School of Computer Engineering, Nanyang Technological University, Singapore 639798

²Biomedical Engineering Research Centre, College of Engineering, Nanyang Technological University, Singapore 637553

³Department of Bioscience and Bioinformatics, School of Computer Science and Systems Engineering, Kyushu Institute of Technology, Fukuoka 820-8502, Japan

⁴Biomedical Informatics Research Center, Kyushu Institute of Technology, Fukuoka 820-8502, Japan

Corresponding author.

Chinh TT Su: sutr0003/at/ntu.edu.sg; Christian Schönbach: schoen/at/bio.kyutech.ac.jp; Chee-Keong Kwoh: asckkwoh/at/ntu.edu.sg

Supplement

Selected articles from the Eleventh Asia Pacific Bioinformatics Conference (APBC 2013): Bioinformatics

Conference

The Eleventh Asia Pacific Bioinformatics Conference (APBC 2013)

21-24 January 2013

Vancouver, Canada

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The pandemic 2009-H1N1 influenza virus circulated in the human population and caused thousands deaths worldwide. Studies on pandemic influenza vaccines have shown that T cell recognition to conserved epitopes and cross-reactive T cell responses are important when new strains emerge, especially in the absence of antibody cross-reactivity. In this work, using HLA-B*4405 and DM1-TCR structure model, we systematically generated high confidence conserved 2009-H1N1 T cell epitope candidates and investigated their potential cross-reactivity against H5N1 avian flu virus.

Results

Molecular docking analysis of differential DM1-TCR recognition of the 2009-H1N1 epitope candidates yielded a mosaic epitope (KEKMNTEFW) and potential H5N1 HA cross-reactive epitopes that could be applied as multivalent peptide towards influenza A vaccine development. Structural models of TCR cross-recognition between 2009-H1N1 and 2004-H5N1 revealed steric and topological effects of TCR contact residue mutations on TCR binding affinity.

Conclusions

The results are novel with regard to HA epitopes and useful for developing possible vaccination strategies against the rapidly changing influenza viruses. Yet, the challenge of identifying epitope candidates that result in heterologous T cell immunity under natural influenza infection conditions can only be overcome if more structural data on the TCR repertoire become available.

Background

In 2009, the outbreak of a new swine-origin strain of influenza A H1N1 caused widespread human infection [1]. One of the most important surface proteins, hemagglutinin (HA) permits the virus to bind to cell membrane and infect the cells. Since mutations enable the virus to escape from either T cell or antibody recognition, current flu vaccines were not effective against the emerging virus. Sequence analyses showed that the HA sequence of the pandemic 2009-H1N1 underwent an antigenic shift [2] that altered its antigenicity in context of the seasonal flu vaccine.

The antigenicity of HA 2009-H1N1 remained highly conserved to pandemic 1918-H1N1 and partially conserved to seasonal flu strains of the 1930s. Therefore, the majority of infected individuals who were vaccinated with the WHO recommended seasonal flu vaccine did not produce neutralizing antibodies against the new influenza strain. However, elderly and individuals born before 1950 were less affected than expected. The lower infection rate of these age groups has been interpreted as the results of cross-reactive T cells [3] and antibody [4] responses to the pandemic 1918-H1N1 and partially cross-reactive T cell response to seasonal flu strains of the 1930s. A study by Boon et al. [5] on CD8⁺T cell recognition of heterosubtypic H1N1 variants indicated that repeated infection with heterologous viruses may increase cross-reactive Cytotoxic T Lymphocytes (CTL) and thus confer protection against newly emerging strains in absence of a cross-reactive antibody response. Further support for this concept comes from a study of subjects who were vaccinated against seasonal influenza and showed in vitro cross-reactive T cell responses against HA of the pandemic 2009-H1N1 [6].

In growing recognition of the role of T cell responses to H1N1, several groups conducted large-scale Human leukocyte antigen (HLA) binding motif scanning analyses of pandemic and seasonal strains to predict and identify conserved peptides that elicit cross-reactive HLA class I and/or class II restricted T cell responses [7-9]. While the affinity-based approach allows a broad coverage of HLA supertypes and epitope bindings [7,8], structural approach gives better insight view onto T cell recognition of the HLA-restricted T cell epitopes [10-12]. In our study, we are interested in immunogenicity that depends on the quality of T-cell receptor (TCR) interaction with the HLA/peptide complexes rather than HLA-binding peptide affinity only. We, therefore, combined affinity-based epitope prediction with molecular docking to generate conserved high confidence HA T cell epitope candidates of current and past pandemic strains, and consequently analyzed the potential TCR cross-recognition of 2009-H1N1 and 2004-H5N1.

According to Archbold et al. complex of DM1-TCR and HLA-B*4405/peptide showed significant enhancement in T cell-mediated responses among micropolymorphisms in the HLA-B*44 family, and as such they are key factors in controlling persistent viral infections [12]. Thus, to perform the experiments we used HLA-B*4405 and DM1-TCR as models. Results of structural models of TCR cross-recognition between 2009-H1N1 and 2004-H5N1 revealed steric and topological effects of TCR contact residue mutations on TCR binding affinity. While these results are novel with respect to HLA-B*4405-restricted H1N1 HA epitopes and DM1-TCR, yet with limited available structural data upon the TCR repertoire, more investigations and experimental analyses are still recommended for further broad perspective of their utility in vaccine development against the emerging virus strains.

Results and discussion

Conserved HA T cell epitope candidates generated for HLA-B*4405 and DM1-TCR

Examining various HA sequences among the pandemic 2009-H1N1, 1918-H1N1, and WHO recommended vaccine strains [Additional file 1], we predicted potential 9-mer T cell epitopes using the tool NetCTL v1.2 from Immune Epitope Database (IEDB) (see Methods). Nineteen candidates, which scored greater than 0.75, are more likely well presented by HLA-B44 family [Additional file 2]. We then docked these 19 epitopes to HLA-B*4405, and subsequently the HLA-B*4405/epitope complex as ligand to DM1-TCR. The 19 predicted epitope candidates differ in their physico-chemical properties. Eight candidates starting at positions 128, 188, 251, 131, 229, 400, 240, and 259 contain mostly hydrophobic and polar residues, whereas other 11 candidates (positions 50, 412, 446, 463, 493, 514, 421, 475, 482, 81, and 274) are composed of predominantly hydrophilic residues [Additional file 3] which result in higher HLA-B*4405 binding energies (Table (Table1).1). As expected, all the 19 epitopes bound to the helical antigen-presenting groove of the HLA-B*4405 [13]. Eleven epitopes (50, 128, 251, 412, 463, 493, 514, 131, 229, 400, and 259) bound in similar orientations to HLA-B*4405 with Glu at position 2 and residues at the C-terminus binding to the B and F pockets of the HLA-B*4405, respectively [13-15]. Residues which occupy the centre of the binding groove are solvent-exposed and likely to bind to TCR [13,16]. In contrast, most residues of epitopes at positions 188, 446, 421, 475, 482, and 240 interacted with the HLA-B*4405 peptide binding pockets. In our model, the deeply embedded residues were not exposed to the solvent. Therefore TCR recognition of HLA-B*4405/epitope complexes is expected to be conformationally restrained.

Table 1

Total binding energies of the 19 epitope candidates (in descending HLA-B*4405 binding energy ranks).

DM1-TCR was docked to the HLA-B*4405/epitope complexes to assess their binding conformation. In the models with minimum binding energies, DM1-TCR V_αand V_βdomains interacted with HLA-B*4405 α₁and α₂domain residues and solvent exposed residues of the epitopes. Epitope candidates 240 and 482 were embedded in the binding groove of HLA-B*4405, and interacted with DM1-TCR via Tyr⁷and Tyr⁸(epitope 240) and Lys⁶(epitope 482) as shown in Table Table2.2. These interactions appeared to be mediated by a change of the TCR binding position to HLA-B*4405 α₁- and α₂-domain residues, resulting in contacts with polar and charged residues Asn⁷⁰, Glu⁷⁶, and Gln¹⁵⁵of the HLA-B*4405. Hydrogen bond lengths (in Å) and dihedrals around these H-bonds made by DM1-TCR and HLA-B*4405 domains in cases of exposed and embedded epitope types were calculated. In case of epitope 259, residues at positions 4, 5, and 6 were exposed while the TCR V_αdomain interacted with Asn⁷⁰(2.1 Å) and Glu⁷⁶(2.2 Å). In contrast, for the embedded-type epitope 240, we observed binding of TCR V_βdomain to Asn⁷⁰and Glu⁷⁶at 2.5 Å H-bond lengths. Epitope candidates 400 (exposed-type) and 482 (embedded-type) also showed similar noticeable H-bond length changes. Distances of the TCR to the residues Gln¹⁵⁵(HLA-α₂) decreased when the contacts with the HLA domains shifted from the TCR V_βto TCR V_α. Meanwhile, the dihedrals between residues that made the H-bonds also showed decreasing trend when the TCR changed its binding positions to the HLA-B*4405 from V_βto V_αdomain (e.g. from -133.7^°to -54.1^°in cases of epitope 240 and 259 respectively) [Additional file 4]. It could suggest that the changes in H-bond lengths and dihedral angles indicate an attempt of the TCR to adjust its binding access to the HLA-B*4405/epitope complexes when the epitopes change from exposed to embedded type.

Table 2

2009-H1N1 HA epitope interacting residues with DM1-TCR and HLA-B*4405 complexes.

Epitope candidates at positions 81 and 274 in 1918 and WHO vaccine sequences [Additional file 2] yielded rather low HLA-B*4405 binding scores (less than threshold 0.75) and could not be docked to DM1-TCR. Therefore it is unlikely that the two candidate epitopes were antigenic to the 1918 and WHO strains. Mutations at positions 81 and/or 274 in HA sequences of the 2009 viral strains increased the HLA-B*4405 binding scores above the threshold, but did not facilitate TCR recognition in our model.

Recognition of computationally inferred optimal epitope KEKMNTEFW by HLA-B4405 and DM1-TCR

We computationally designed the mosaic epitope candidate KEKMNTEFW from five epitope sequences, which were in the top 5 ranks of DM1-TCR binding energy (Table (Table1).1). These epitopes are at positions 463, 482, 412, 475, and 400, whose corresponding residue positions were favourably bound by the DM1-TCR model. We selected the epitope IEKMNTQFT at position 400 as the starting point because most of its residues made direct contacts with DM1-TCR, i.e. -EKMNT---(Table -EKMNT---(Table2).2). Also, Archbold et al. [12] suggested that the second positioned residue Glu (E²) be required for preferential binding to HLA-B44. According to our top 5 DM1-TCR docking results, 2 out of 5 epitopes (412 and 475) contain residue Lys (K) at the first position, and Lys^epitope475directly interacted with the DM1-TCR. Therefore, we used Lys (K¹) for the first position of the mosaic epitope. Similarly, we chose Glu (E) for the 7^thposition since it was a TCR-interacting residue of the epitope 412. Finally, we used bulky side-chains of F⁸(Phe) and W⁹(Trp) serving as anchors for HLA-B*4405 binding. Thus, using Deep-View [17], we substituted residues I¹, Q⁷, and T⁹with K, E, and W respectively.

Docking of the mosaic epitope KEKMNTEFW to HLA-B*4405 and DM1-TCR showed that it bound favourably to both HLA-B*4405 (binding energy -849.5 kcal/mol; rank 4) and DM1-TCR (-684.4 kcal/mol; rank 6) with Asn⁵and Thr⁶exposed to the solvent and directly interacting with DM1-TCR. Although the HA peptide appears to be a good candidate for inclusion in multivalent peptide vaccine against the H1N1 influenza A, its efficacy as a protective epitope on population level depends on the TCR repertoire which could be only tested experimentally.

Cross-recognition of 2009-H1N1 and 2004-H5N1 HA T cell epitope candidates

A study by Kreijtz et al. [18] showed that T cell responses to seasonal H1N1 and H3N2 strains are largely cross-reactive to avian H5N1. According to WHO Global Influenza Program [19], H5 HA viral strain A/Vietnam/1194/2004 of the avian flu outbreak in Vietnam was one of the H5N1 prototype vaccine strains in 2005 and recommended candidate of pre-pandemic H5N1 vaccine. Therefore, we used HA protein of this strain as a model to test if our 2009-H1N1 T cell epitope candidates would be cross-reactive for 2004-H5N1.

NetCTL v1.2 was used to extract the 2004-H5N1 HLA-B*4405 restricted T cell epitopes candidates from IEDB. Of all candidates with predicted scores greater than 0.75, seven were highly similar (greater than 78% similarity) to the 2009-H1N1 T cell epitope candidates (Table (Table3)3) and likely to be recognized by DM1-TCR.

Table 3

Seven 2009-H1N1 T cell epitope candidates that could be cross-reactive with 2004-H5N1 T cell responses.

Docking of the seven HLA-B*4405/2004-H5N1 epitope complexes to DM1-TCR revealed that the DM1-TCR predominantly interacted with the 2004-H5N1 epitopes at conserved positions 50, 446, 493, and 475. DM1-TCR binding energies of the 2004-H5N1 epitope candidates were lower and thus more favourable than these of the corresponding 2009-H1N1 epitope candidates (Table (Table3).3). Most mutations that occurred between these two influenza outbreaks did not appear to affect DM1-TCR recognition of HLA-B*4405 presented epitope candidates.

However, we observed a significant decrease in TCR binding energy of the epitope candidate 2004-H5N1 complex at position 50 (Table (Table3).3). The mutation K4T changed the structural conformation of the epitope's exposed region. The side chain of the mutated Thr⁴pointed toward the HLA-α₂domain and is embedded in the helical binding groove of the HLA-B*4405. It might therefore induce the interactions of Lys⁸and Leu⁹at its C-terminal with the DM1-TCR (Figure (Figure1A).1A). This could consequently suggest a more favourable binding of DM1-TCR to the HLA-B*4405/epitope50 in 2004-H5N1 than in 2009-H1N1 viral strain.

Figure 1

Conformational changes of DM1-TCR/HLA-B*4405/epitope complexes caused by epitope mutations. (A) Mutation K4T in the exposed region of 2004-H5N1 epitope 50 induced interaction of the C-terminal Lys⁸and Leu⁹with DM1-TCR. (B) Reduced exposed DM1-TCR (grey) (more ...)

In addition, we noticed that the binding affinity of DM1-TCR to the 2004-H5N1 epitope candidates considerably decreased when the TCR interactions occurred directly at mutated residues of the epitope candidates at position 412 (H5N) and 421 (V8M and D9E). Substitution of a positively charged His with a smaller-sized neutral Asn reduced the contact surface of the epitope candidate's exposed region (Figure (Figure1B),1B), resulting in a conformationally constrained contact of DM1-TCR with 2004-H5N1 candidate epitope 412 and a higher binding energy (-640.8 kcal/mol) compared to the 2009-H1N1 candidate epitope 412. In a future pandemic we expect that apart from a few mutated epitopes, heterologous immunity [20] mediated by pre-existing cross-reactive T cell responses to seasonal influenza virus will limit its severity and extent.

Conclusions

The HLA-B*4405 and DM1-TCR docking models showed differential recognition of the 2009-H1N1 HA T cell epitope candidates, reflecting the topological constraints of the epitopes. This information was used to derive the synthetic H1N1 epitope KEKMNTEFW with optimal recognition of both HLA-B*4405 and DM1-TCR models and to identify likely cross-reactive 2004-H5N1 epitopes. While the results are novel with regard to HLA-B*4405-restricted H1N1 HA epitopes, their utility in vaccination strategies against influenza viruses is limited by the fact that the T cell responses to viruses depend on the TCR repertoire, and in particular on the nature of TCR alpha chain and their conformation as shown in a study by Zhong et al. [21]. To simulate a T cell response to H1N1 epitopes on population level as it is desirable for vaccine design, a large number of crystal structure data on TCR Vα and Vβ chains and their heterodimers would be necessary to computationally assess epitope candidates for their potential to induce a broad T cell response.

Methods

Obtaining HA candidate epitopes from pandemic (H1N1) 2009 sequences

Potential epitopes were predicted using T cell epitope prediction tool (NetCTL v1.2) from IEDB [22,23]. NetCTL, a neural network architecture-based tool, was used to predict T cell epitope candidates for HA proteins of current H1N1 influenza A strains according to HLA-B44 supertype. Weight parameters on C-terminal cleavage (0.15) and transporter associated with antigen processing (TAP) efficiency (0.05) were as default. There are 3 threshold scores (0.75, 0.9, 1.0) that give both high sensitivity (0.8, 0.74, 0.7) and specificity (0.97, 0.98, 0.985) accordingly. While the first 2 scores (0.75 and 0.9) obtained similar results of T cell epitopes, the score of 1.0 resulted only 7 epitopes (positions 240, 188, 128, 482, 400, 131, and 50) shown in Table Table1.1. Our docking results of HLA-B*4405 and the T cell epitope candidates showed that epitope candidates at positions 259, 251, and 229, which were located in the top 10 HLA-binding energy rankings in Table Table1,1, would be missed if the 1.0 score was used.

Finally, as comparing to the score of 0.9, we selected 0.75 as the threshold for its better sensitivity (0.8) to predict the potential T cell epitopes. Therefore candidates with prediction scores greater than 0.75 were chosen for further investigation. I-TASSER [24] was used to obtain homology models of the selected T cell epitopes.

Molecular docking of predicted HLA-B*4405-binding epitopes to T cell receptor DM1-TCR

The pipeline included docking the epitopes to HLA-B*4405 [PDB:3DX8] and followed by docking of the HLA/epitope complex as a ligand to DM1-TCR [PDB:3DXA]. The binding ability of the predicted epitopes was further analyzed using ClusPro v.2 [25,26].

ClusPro v.2 is a web-based automated docking program performing a multistage protocol: rigid PIPER docking, filtering and clustering of docked conformations, and stabilizing using Monte Carlo simulations [26]. During the docking, HLA β-domain was masked but remained surface accessible since it is not involved in interaction with the TCR [13]. The results were clustered according to their binding energies. The binding energy score (hereby called "binding energy") is generated from an energy function of PIPER docking program. This function is a sum of potential terms of shape complementarity, electrostatics, desolvation contributions, and Decoys as reference states (DARS) [25]. According to Kozakov et al., the core idea of the knowledge-based potential DARS counts on observed numbers of intermolecular interactions [25]. Therefore we filtered our docking results by selecting docked complexes that belonged to the most populated clusters of interacting complexes but with lowest binding energy scores for our final results. We assumed that the model with minimum binding energy was the optimal conformation.

Then, we performed molecular dynamics (MD) simulations using AMBER 10 force field ff99SB [27] to improve the bound conformation of rigid docking. The TCR-HLA/epitope docked complexes underwent a 3-stage MD simulation (minimization, heating, and equilibration) using explicit solvent model under periodic boundary condition. In the minimization process, we applied a weak positional restraint using a force constant of 500 kcal/molÅ²on the whole complex during the first 1,000 steps under restrained conditions, while initially minimizing positions of solvent and sodium ions. For the subsequent 2,500 steps of minimization, we removed this restraint. The constant volume was set during both the 2 stages of the minimization process. In the heating stage of 20 ps, we restrained the complex again, but with only 10 kcal/molÅ²to avoid wild fluctuations in the structure. We allowed the system to heat up from 0 K to 300 K and applied the Langevin temperature equilibration scheme to control the temperature. Then, a short equilibration stage (1ns) without the restraints was performed in constant pressure of 1 atm and at 300 K. We used SHAKE in both heating and equilibration stages to constrain bonds that involves hydrogen. As a result, complexes obtained from the MD simulation above were considered final bound conformations of the docked TCR-HLA/epitope complexes in our study.

List of abbreviations

Some abbreviations were used in the text: HA: (Hemagglutinin); HLA: (Human leukocyte antigen); TCR: (T cell Receptor); CTL: (Cytotoxic T Lymphocyte); MHC: (Major histocompatibility complex); TAP: (Transporter associated with antigen processing); DARS: (Decoys as the Reference States); MD: (Molecular Dynamics).

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CTTS carried out molecular docking experiments. CTTS, CS and CKK wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by Singapore MOE AcRF Grant No: MOE2008-T2-1-1074 and Jardine OneSolution JOS-M4060054.

Declarations

Funding for publication of this work was supported by Singapore MOE AcRF Grant No: MOE2008-T2-1-1074 and Jardine OneSolution JOS-M4060054.

This article has been published as part of BMC Bioinformatics Volume 14 Supplement 2, 2013: Selected articles from the Eleventh Asia Pacific Bioinformatics Conference (APBC 2013): Bioinformatics. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcbioinformatics/supplements/14/S2.

Supplementary Material

Additional file 1

MAFFT multiple sequence alignment of pandemic strains (2009 - the top 7 sequences) HA proteins to HA (1918 - South Carolina) and WHO vaccine HA (the last 3 sequences).

Click here for file^{(494K, pdf)}

Additional file 2

Predicted HA T cell epitopes of H1N1 2009 strains compared to 1918 and WHO-1999-2006-2007 strains.

Click here for file^{(39K, xls)}

Additional file 3

Physicochemical properties of NetCTL-predicted HLA-B44 restricted T cell epitope candidates (A) and non-epitopes (B).

Click here for file^{(93K, pdf)}

Additional file 4

Residues of domain α1, α2 of HLA-B*4405 interacting with DM1-TCR.

Click here for file^{(67K, pdf)}

Acknowledgements

We thank Stephanus Daniel Handoko for helpful discussion.

References

Smith GJD, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, Raghwani J, Bhatt S. et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459:1122–1125. doi: 10.1038/nature08182. [PubMed] [Cross Ref]
Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol. 2009;45(3):174–178. doi: 10.1016/j.jcv.2009.06.004. [PubMed] [Cross Ref]
Gras S, Kedzierski L, Valkenburg S, Laurie K, Liu Y, Denholm J, Richards M, Rimmelzwaan G, Kelso A, Doherty P. et al. Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci USA. 2010;107(28):12599–12604. doi: 10.1073/pnas.1007270107. [PubMed] [Cross Ref]
Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. Science. 2010;328:357–360. doi: 10.1126/science.1186430. [PMC free article] [PubMed] [Cross Ref]
Boon ACM, Mutsert Gd, Baarle Dv, Smith DJ, Lapedes AS, Fouchier RAM, Sintnicolaas K, Osterhaus ADME, Rimmelzwaan GF. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. The Journal of Immunology. 2004;172:2453–2460. [PubMed]
Subbramanian R, Basha S, Shata M, Brady R, Bernstein D. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T-cell responses elicited by seasonal influenza vaccination. Vaccine. 2010;28(52):8258–8267. doi: 10.1016/j.vaccine.2010.10.077. [PubMed] [Cross Ref]
Assarsson E, Bui H-H, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H. et al. Immunomic analysis of the repertoire of T-cell specificities for Influenza A Virus in Humans. Journal of Virology. 2008;82(24):12241–12251. doi: 10.1128/JVI.01563-08. [PMC free article] [PubMed] [Cross Ref]
Groot ASD, Ardito M, McClaine EM, Moise L, Martin WD. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine. 2009;27:5740–5747. doi: 10.1016/j.vaccine.2009.07.040. [PubMed] [Cross Ref]
Gupta SK, Srivastava M, Akhoon BA, Smita S, Schmitz U, Wolkenhauer O, Vera J, Gupta SK. Identification of immunogenic consensus T-cell epitopes in globally distributed influenza A H1N1 neuraminidase. Infect Genet Evol. 2010;11(2):308–319. [PubMed]
Wang JH, Reinherz EL. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol Immunol. 2002;38:1039–1049. doi: 10.1016/S0161-5890(02)00033-0. [PubMed] [Cross Ref]
Chang H-C, Smolyar A, Spoerl R, Witte T, Yao Y, Goyarts EC, Nathenson SG, Reinherz EL. Topology of T cell Receptor-peptide/Class I MHC interaction defined by charge reversal complementation and functional analysis. J Mol Biol. 1997;271:278–293. doi: 10.1006/jmbi.1997.1169. [PubMed] [Cross Ref]
Archbold JK, Macdonald WA, Gras S, Ely LK, Miles JJ, Bell MJ, Brennan RM, Beddoe T, Wilce MCJ, Clements CS. et al. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J Exp Med. 2009;206(1):209–219. doi: 10.1084/jem.20082136. [PMC free article] [PubMed] [Cross Ref]
Reinherz EL, Tan K, Tang L, Kern P, Liu J-h, Xiong Y, Hussey RE, Smolyar A, Hare B, Zhang R. et al. The Crystal Structure of a T Cell Receptor in Complex with Peptide and MHC Class II. Science. 1999;286:1913–1921. doi: 10.1126/science.286.5446.1913. [PubMed] [Cross Ref]
DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian Population. Biochemistry. 1995;34:10130–10138. doi: 10.1021/bi00032a005. [PubMed] [Cross Ref]
Macdonald WA, Purcell AW, Mifsud NA, Ely LK, Williams DS, Chang L, Gorman JJ, Clements CS, Kjer-Nielsen L, Koelle DM. et al. A Naturally Selected Dimorphism within the HLA-B44 Supertype Alters Class I Structure, Peptide Repertoire, and T Cell Recognition. The Journal of Experimental Medicine. 2003;198(5):679–691. doi: 10.1084/jem.20030066. [PMC free article] [PubMed] [Cross Ref]
Wahl A, McCoy W, Schafer F, Bardet W, Buchli R, Fremont DH, Hildebrand WH. T-Cell Tolerance for Variability in an HLA Class I-Presented Influenza A Virus Epitope. Journal of Virology. 2009;83(18):9206–9214. doi: 10.1128/JVI.00932-09. [PMC free article] [PubMed] [Cross Ref]
Guex N, Peitsch MC. Swiss-Model and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis. 1997;18:2714–2723. doi: 10.1002/elps.1150181505. [PubMed] [Cross Ref]
Kreijtz JHCM, Mutsert Gd, Baalen CAv, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF. Cross-Recognition of Avian H5N1 Influenza Virus by Human Cytotoxic T-Lymphocyte Populations Directed to Human Influenza A Virus. Journal of Virology. 2008;82(11):5161–5166. doi: 10.1128/JVI.02694-07. [PMC free article] [PubMed] [Cross Ref]
Availability of new H5N1 prototype strain for influenza pandemic vaccine development. http://www.who.int/influenza/vaccines/virus/2strains2006/en/
Selin LK, Welsh RM. Plasticity of T Cell Memory Responses to Viruses. Immunity. 2004;20:5–16. doi: 10.1016/S1074-7613(03)00356-X. [PubMed] [Cross Ref]
Zhong W, Dixit SB, Mallis RJ, Arthanari H, Lugovskoy AA, Beveridge DL, Wagner G, Reinherz EL. CTL Recognition of a Protective Immunodominant Influenza A Virus Nucleoprotein Epitope Utilizes a Highly Restricted Vβ but Diverse Vα Repertoire: Functional and Structural Implications. J Mol Biol. 2007;372:535–548. doi: 10.1016/j.jmb.2007.06.057. [PubMed] [Cross Ref]
Larsen M, Lundergard C, Lamberth K, Buus S, Brunak S, Lund O, Nielsen M. An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. European Journal of Immunology. 2005;35(8):2295–2303. doi: 10.1002/eji.200425811. [PubMed] [Cross Ref]
Larsen M, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 2007;8(1):424. doi: 10.1186/1471-2105-8-424. [PMC free article] [PubMed] [Cross Ref]
Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725–738. doi: 10.1038/nprot.2010.5. [PMC free article] [PubMed] [Cross Ref]
Kozakov D, Brenke R, Comeau SR, Vajda S. PIPER: An FFT-based protein docking program with pairwise potentials. Proteins. 2006;65:392–406. doi: 10.1002/prot.21117. [PubMed] [Cross Ref]
Kozakov D, Hall DR, Beglov D, Branke R, Comeau SR, Shen Y, Li K, Zheng J, Vakili P, Paschalidis IC. et al. Achieving reliability and high accuracy in automated protein docking: ClusPro, PIPER, SDU, and stability analysis in CAPRI rounds 13-19. Proteins. 2010;78:3124–3130. doi: 10.1002/prot.22835. [PMC free article] [PubMed] [Cross Ref]
Case DA, Cheatham TE III, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling S, Wang B, Woods R. The Amber biomolecular simulation programs. J Computat Chem. 2005;26:1668–1688. doi: 10.1002/jcc.20290. [PMC free article] [PubMed] [Cross Ref]

Articles from BMC Bioinformatics are provided here courtesy of
BioMed Central